{"created":"2023-05-15T14:46:16.966194+00:00","id":63217,"links":{},"metadata":{"_buckets":{"deposit":"b0e8e781-f258-4e01-add2-8ea138eee130"},"_deposit":{"created_by":1,"id":"63217","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"63217"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00063217","sets":["10:29"]},"author_link":["624339","624340","624341"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2009-09-13","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background;Selective serotonin reuptake inhibitors(SSRIs)including paroxetine have severe stimulant effect in their starting doses and at the time of dose escalation which is now called as activatioin syndrome. The main features of this phenomenon are abrupt uprising of agitaion and impulsivity, but activation syndrome by SSRIs resembling acutr phase of schizophrenia are rare.\nMethod;A case study of paroxetine induced hallucinatory-delusional state with non-systematic review of Literature. Results;A50years ofd male with first episode of moderate major depressive disorder(MDD)was subsided within 6weeks. He had no previous histrory of psychiatric disorders and had been in good social status with honest living until he got the sick leave by MDD.on returning work, his dosing of paroxeitine was uprisen to 30mg per day. After three days of dose escalation, he had auditory hallucination and persecutory delusion which resembled acute phase of schizophrenia, but had no sign of mania or hypomania as well as agitation or impulsivity. The hallucinatory-delusional state was gradually resolved with dose reduction of paroxetine. Literature search revealed activation syndrome with psychotic feature is rare. Conclusion;Discerning activation syndrome is clinically imprtant for this side effect impairs course of pathologic process. But those with psychotic feature could be easily misdiagnosed as acute onset schizophrenia if we have no idea of this phenomenon.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"The Kobe conference of the International Neuropsychiatic Association","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Saio, Takeo"}],"nameIdentifiers":[{"nameIdentifier":"624339","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kurihara, Chieko"}],"nameIdentifiers":[{"nameIdentifier":"624340","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"栗原 千絵子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"624341","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Paroxetine induced psychose - activation syndrome with distinct psychotic feature -","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Paroxetine induced psychose - activation syndrome with distinct psychotic feature -"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2009-09-07"},"publish_date":"2009-09-07","publish_status":"0","recid":"63217","relation_version_is_last":true,"title":["Paroxetine induced psychose - activation syndrome with distinct psychotic feature -"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T21:21:52.160636+00:00"}